SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform,

SOUTH SAN FRANCISCO, Calif. , July 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody ® technology platform, today

CX-2029 is the first CD71-targeting antibody-drug conjugate (ADC) administrated to patients, with a generally well-tolerated safety profile at doses that elicit anti-tumor responses SOUTH SAN FRANCISCO, Calif. , June 21, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif. , May 27, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today

SOUTH SAN FRANCISCO, Calif. , May 06, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today

SOUTH SAN FRANCISCO, Calif. , April 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody ® technology

SOUTH SAN FRANCISCO, Calif. , April 14, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology

SOUTH SAN FRANCISCO, Calif. , March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody ® technology

-Broad advancement of clinical pipeline- -Three-arm Phase 2 study of praluzatamab ravtansine (CX-2009) launched in breast cancer- -Enrollment continues in Phase 2 expansion study of CX-2029 in four cancer types, in partnership with AbbVie- -Bristol Myers Squibb expands anti-CTLA-4 Probody Program

SOUTH SAN FRANCISCO, Calif. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody ® technology platform,